Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright's target price suggests a potential upside of 148.62% from the stock's previous close.
Separately, Chardan Capital restated a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday.
Get Our Latest Stock Report on COYA
Coya Therapeutics Stock Performance
COYA stock traded up $0.03 during trading on Monday, hitting $7.24. The company had a trading volume of 86,255 shares, compared to its average volume of 71,626. The firm has a 50-day moving average price of $7.02 and a 200-day moving average price of $7.03. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15. As a group, equities research analysts forecast that Coya Therapeutics will post -1.27 EPS for the current year.
Institutional Trading of Coya Therapeutics
A number of institutional investors have recently bought and sold shares of COYA. Vanguard Group Inc. increased its position in Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company's stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. Gilbert & Cook Inc. acquired a new position in shares of Coya Therapeutics in the second quarter valued at $61,000. Renaissance Technologies LLC bought a new stake in Coya Therapeutics in the second quarter valued at about $101,000. Finally, GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics in the 3rd quarter worth approximately $169,000. Institutional investors and hedge funds own 39.75% of the company's stock.
Coya Therapeutics Company Profile
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Further Reading
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
